Literature DB >> 18000680

Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma.

Enrique Lerma1, Marisa Romero, Alberto Gallardo, Cristina Pons, Josefina Muñoz, Josefina Fuentes, Belen Lloveras, Lluis Catasus, Jaime Prat.   

Abstract

We studied whether Fas-receptor (Fas-R; CD95) expression, single-nucleotide polymorphisms (SNPs) in the Fas promoter region, and/or Fas-ligand (Fas-L) production could determine individual susceptibility to cervical cancer progression. The clinicopathologic features of 38 patients with cervical squamous carcinomas (22 stage I, 8 stage II, and 8 stage III+) were reviewed and related with: (a) Fas-R expression by immunohistochemistry; (b) Fas-R SNPs at -670 and -1377 locations by restriction fragment length polymorphism and DNA sequencing; and (c) Fas-L expression by immunohistochemistry. Overall and disease-free survival curves showed significant differences in relation to stage (p < 0.001). Fas-R was identified in 20 of 38 (52.6%) tumors without statistical differences in survival, stage, or Fas-L overproduction. Fas-R GG genotype was more common than expected in advanced tumors (p = 0.065). The Fas-R-1377A allele and AA genotype were unrelated with survival, stage, or Fas-R expression. Fas-L overproduction was detected in 20 of 38 (52.6%) tumors; it was more frequent in advanced-stage tumors and was inversely related to survival (p = 0.03) and decrease in host inflammatory response (p = 0.01). Fas-R expression by tumor cells seems unrelated to stage or lymphoid infiltrate. Tumor production of Fas-L may represent an attempt to destroy the host's lymphocytic reaction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000680     DOI: 10.1007/s00428-007-0535-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  45 in total

1.  Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.

Authors:  D Vidal; X Matías-Guiu; A Alomar
Journal:  Clin Exp Dermatol       Date:  2004-09       Impact factor: 3.470

2.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

3.  Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.

Authors:  C Moers; U Warskulat; M Müschen; J Even; D Niederacher; R Josien; U Koldovsky; M W Beckmann; D Häussinger
Journal:  Int J Cancer       Date:  1999-02-09       Impact factor: 7.396

4.  Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction.

Authors:  Hung-Cheng Lai; Wei-Yu Lin; Ya-Wen Lin; Cheng-Chang Chang; Mu-Hsien Yu; Chia-Chi Chen; Tang-Yuan Chu
Journal:  Gynecol Oncol       Date:  2005-10       Impact factor: 5.482

5.  Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder.

Authors:  S H Lee; M S Shin; W S Park; S Y Kim; S M Dong; J H Pi; H K Lee; H S Kim; J J Jang; C S Kim; S H Kim; J Y Lee; N J Yoo
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

6.  Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production.

Authors:  G A Stanczuk; E N Sibanda; C Perrey; M Chirara; V Pravica; I V Hutchinson; S A Tswana
Journal:  Int J Cancer       Date:  2001-12-15       Impact factor: 7.396

7.  HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity.

Authors:  R J Apple; H A Erlich; W Klitz; M M Manos; T M Becker; C M Wheeler
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

Review 8.  The CD95(APO-1/Fas) DISC and beyond.

Authors:  M E Peter; P H Krammer
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

9.  Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection.

Authors:  L Kjellberg; G Hallmans; A M Ahren; R Johansson; F Bergman; G Wadell; T Angström; J Dillner
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

10.  Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.

Authors:  H Das; T Koizumi; T Sugimoto; S Chakraborty; T Ichimura; K Hasegawa; R Nishimura
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

View more
  6 in total

Review 1.  Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes.

Authors:  Shing Cheng Tan; Ravindran Ankathil
Journal:  Tumour Biol       Date:  2015-08-05

2.  FAS-670 gene polymorphism and cervical carcinogenesis risk: A meta-analysis.

Authors:  Qiaoying Huang; Jie Wang; Yanling Hu
Journal:  Biomed Rep       Date:  2013-08-20

Review 3.  The role of CD95 and CD95 ligand in cancer.

Authors:  M E Peter; A Hadji; A E Murmann; S Brockway; W Putzbach; A Pattanayak; P Ceppi
Journal:  Cell Death Differ       Date:  2015-02-06       Impact factor: 15.828

4.  A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival.

Authors:  Guenter Hofmann; Uwe Langsenlehner; Tanja Langsenlehner; Babak Yazdani-Biuki; Heimo Clar; Armin Gerger; Florentine Fuerst; Hellmut Samonigg; Peter Krippl; Wilfried Renner
Journal:  J Cell Mol Med       Date:  2009-02-27       Impact factor: 5.310

5.  Lack of association between Fas rs180082 polymorphism and risk of cervical cancer: an update by meta-analysis.

Authors:  Xu Chen; Wuning Mo; Qiliu Peng; Xiandu Su
Journal:  BMC Med Genet       Date:  2013-07-16       Impact factor: 2.103

6.  FasL gene -844T/C mutation of esophageal cancer in South China and its clinical significance.

Authors:  Hongguang Zhao; Linfeng Zheng; Xinru Li; Lifang Wang
Journal:  Sci Rep       Date:  2014-01-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.